The first two authors contributed equally to this work Autoantibodies (rheumatoid factor, RF; anti-citrullinated-protein antibodies,ACPA) and complement system are involved in rheumatoid arthritis (RA). ACPA and anti-TNF agents are capable of in vitro modulating complement activity. We investigated the relationships between complement, autoantibodies, and anti-TNF treatment in vivo. One-hundred fourteen RA patients (89F/25M), diagnosed according to 1987 ACR criteria, and 30 healthy controls were enrolled. Serological analysis included ESR, CRP, complement C3, C4 and CH50, RF and ACPA (ELISA, cut-off>20U/ml). Split-products (SP) of C3 and B were studied by immunoelectrophoresis/counterimmunoelectrophoresis. Seventy-six patients started anti-TNF treatment and were studied at baseline and after 22 weeks. Disease activity was measured with DAS28 and response to therapy with EULAR criteria. At baseline, RA patients showed significantly higher levels of C3 and C4 than controls (C3 127.9±26.5 vs 1l0±25mgldl, P=O.0012; C4 29.7±10.2 vs 22.7±8.3mgldl, P=0.0003). No differences in C3, C4 and CH50 levels were observed between ACPA+ (n=76) and ACPA-(n=38) patients. After 22 weeks of anti-TNF, C3, C4 and RF were significantly reduced (P<0.003, <0.005 and <0.04, respectively) and RF changes showed negative correlation with CH50. SP of C3 and B were observed neither at baseline nor after 22 weeks. DAS28 significantly improved after 22 weeks. Patients showing higher baseline C3 or lower reduction of C3 levels after 22 weeks had a worse EULAR outcome (x2=22.793, P<O.OOI). RF levels seem to correlate with complement CH50. The presence of high levels of C3 in RA patients may reflect a pro-inflammatory status and represent a negative prognostic factor for anti-TNF therapy.
Hallmark of the disease are circulating autoantibodies, specifically rheumatoid factors (RF) and anti-citrullinated protein/peptide antibodies (ACPA), that seem to be involved in the pathogenesis and can be useful as diagnostic and prognostic tools (2) . The relevance of ACPA in determining disease development is evident from several studies. It has been shown that ACPA may appear before clinical symptoms of arthritis. Moreover, a positive ACPA test predicts the future development of erosive RA, and this effect seems synergic with RF. Thus, the presence of ACPA may identify at an early stage those individuals likely to develop a more severe disease outcome (3) . Some of the mechanisms of action of these autoantibodies in the disease pathogenesis are still incompletely understood.
The complement system is an integral part of the immune defence system essential against pathogens and in immune complex clearance. Complement activation leads into the formation of C3 convertase, with cleavage of C3, and production of biologically active complement fragments resulting in opsonization, chemotaxis, and cytolysis (4) .
Complement system plays a pathogenic role in RA. Deposition of complement fragments has been observed in the synovium and can be visualized by immunochemistry in the patients. The locus TRAFI-C5, where the gene encoding is located for complement component C5, has been found strongly associated with an increased risk ofRA, in particular with ACPA positive profile, and correlates with radiographic progression of the disease (5) .
In one study, Trouw and colleagues recently showed that the addition ofACPA to normal human serum can lead to complement activation via both the classical and the alternative pathways (6) . However, no studies have been performed in vivo to address this in vitro effect ofACPA.
In the present study, we investigated the correlation between RF, ACPA, and complement C3 C4, and CH50 levels in a cohort ofRA patients, and the effects of anti-TNF treatment.
MATERIALS AND METHODS

Patients
One-hundred and fourteen Caucasian patients (89 females, 25 males) affected by RA diagnosed according to American College of Rheumatology (ACR) criteria 1987 (7) , were enrolled in the Unit of Rheumatology, Policlinico Tor Vergata, University of Rome Tor Vergata. Thirty healthy subjects served as controls.
Clinical assessment
Data were collected on a standardized, computerized, electronically filled form, including demographic characteristics, date of diagnosis, co-morbidities, past and present medications. Clinical evaluation included swollen and tender joints count, patient's and physician's global assessment using a visual analogue scale (VAS, range 0-100 mm). Disease activity was measured with the Disease Activity Score in 28 joints (DAS28) (8) , and the clinical response was evaluated according to the European League Against Rheumatism (EULAR) response criteria (9) .
Prior to enrolment, all the patients were naive for biologic therapy. At baseline, 96% of the patients were treated with at least one DMARD plus prednisone [48 (42.1%) with methotrexate, 21 (18.4%) with hydroxychloroquine, 13 (11.4%) with a combination of the two, 22 (19.3%) with sulfasalazine, 4 (4.6%) with leflunomide, and 2 (2.3%) with cyclosporine], and 4 (4%) with prednisone alone. Methotrexate was administered by intramuscular injection in all cases; thirty patients assumed 15 mg/week, sixteen patients 10 mg/week, and fifteen 7.5 mg/week. Hydroxychloroquine was administered at the standard dose of 400 mg/day, sulfasalazine 2 g/day, leflunomide 20 mg/day, cyclosporine 3 mg/kg/day, Mean dosage of prednisone equivalents was 83.8±45.3 mg/week. Seventy-six patients started anti-TNF therapy because they were inadequate responders to conventional DMARD therapy (DAS28 > 3.2 and/or with evidence of radiographic disease progression despite at least three months of therapy with one or more DMARDs, one of which was a first line DMARD (methotrexate or leflunomide), if not contraindicated, given alone or in combination at the highest tolerated dosage). Patients were treated by means of either adalimumab (40 mg every other week, subcutaneously, Humira, Abbott Immunology, USA, n=27) or etanercept (50 mg once a week, subcutaneously, Enbrel, Wyeth, USA, n=49). Patients undergoing anti-TNF treatment were evaluated also at 14 and 22 weeks of follow-up. In all the patients, DMARDs and steroids were maintained stable during the follow-up. To exclude the presence of any clinical or laboratory sign ofdisease in the control group, the subjects underwent a study protocol that included clinical history, physical examination and laboratory evaluation. This included complement study (C3, C4, and total haemolytic complement (THC), see below for the assessment). Antibody screening included ACPA and RF. Furthermore, blood count, serum immunoelectrophoresis, erythrocytes sedimentation rate, C-reactive protein, and search for HBV, HCV and HIV were performed. Subjects were excluded if suffering from any disease or testing positive to at least one of these assays, and/or showing positive familial history for immunological disorders, diabetes and coronary artery disease, and/or were assuming any drugs for the month previous to enrolment.
Laboratory analysis
Blood samples were collected at baseline from all subjects and from patients undergoing anti-TNF treatment also at 14 and 22 weeks. In patients starting anti-TNF therapy, the blood samples were obtained two hours before the anti-TNF injection. Sera were collected using standard protocols and stored at -70°C until use. The local medical ethics committee, in compliance with the Helsinki declaration, approved the collection and use of the patient samples. All the patients provided informed consent. Serum IgM RF was detected with a turbidimetric method (Dade Behring, Germany). Values above 40 IVlml were considered positive. Serum IgG ACPA levels were determined by a second-generation anti-CCP-2 antibody QUANTA Lite CCP IgG enzyme-linked immunosorbent assay (ELISA) (Medical Technology Promedt Consulting GmBH, Germany; intra and inter assay variation of 6% and 9%, respectively) and considered positive above a cut off value of 20 U/ml. The range of measurement was 0-300 U/ml, and all values higher than this upper limit were truncated and considered 300 U/ml for the analysis. For each patient, ESR and C-reactive protein (CRP) levels were also determined.
Complement assays. In all the subjects reported herein, C4 concentrations were studied by means of radial immunodiffusion (mg/dl), and C3 by nephelometry according to standard methods (mg/dl) (11). Total hemolytic complement (THC) activity was measured by the Mayer's 50 percent hemolysis method (expressed as CH50, U/ml), as reported previously (12) . Normal values were considered the mean observed in healthy subjects ±2 standard deviations (SD).
Immunochemical analysis. The presence of split products (SP) of C3 and B in the sera was investigated with immunoelectrophoresis (IEP) and counterimmuno electrophoresis (CIE). IEP was performed as previously reported (10) in 1% agarose containing 10 mM EDTA, for 120-150 min at 5 rnA constant current/slide. CIE was carried out in 0-6% agarose containing 40 mM EDTA (10) . The antisera employed in IEP were anti-f3lC/f3lA and anti-factor B; the antiserum employed in CIE was anti-f3lC/f3lA. These antisera were found to contain antibodies directed against the native molecules as well as the respective SP (10) . The antisera directed against ClINH, Clq, CIs, C3 (betaC/betaA), C4, C5, C9 were purchased from the Behring Institute; those against C2, C6, C7, C8, H, I, B, were purchased from Miles; anti-C8 was from Cordis. The antisera employed in IEP were anti-betaC/betaA (Behring Institute) and anti C3-proactivator (B) (Behring Institute).
Statistical analysis
The statistical calculations were performed using Graph Pad 5.0 statistical software (GraphPad Prism, San Diego, CA, USA). Normally distributed variables were summarized using the mean±SD, and non-normally distributed variables by the median and range. Mann Whitney test, Wilcoxon's matched pairs test and paired t test were performed accordingly. Univariate comparisons between nominal variables were performed by chisquare (X 2 ) test or Fisher test where samples were <100. One-way analysis of variance (ANOVA) was used to compare laboratory parameters between the baseline, 14 and 22 weeks of follow-up. Bonferroni post-test was used accordingly (P ). For assessment ofthe correlation between two continuous variables, we used Pearson's and Spearman's correlation coefficient for normal and nonnormal variables, respectively. A multivariable regression analysis was performed to explore any association between EULAR response and RF, ACPA, C3, C4, and CH50. Two-tailed p values were reported, p values < 0.05 were considered significant.
RESULTS
Demographic characteristics
One hundred and fourteen patients (78.1% female, 21.9% male, mean age 55.9±13.2 years), were evaluated in a prospective study. At baseline, most of the patients had an established disease, with mean disease duration of 8.2 years at baseline (range 0-49). Patients were therefore categorized into 4 groups according to the presence or absence of ACPAand/or RF.The groups were homogeneous for age, sex, disease duration, and disease activity. The group with ACPA positive and RF positive profile was the largest with 63 (55.2%) patients. ACPA positive patients were cumulatively 78 (68.4%), while completely seronegative patients were 21 (18.4%) ( Table I) .
Most of the patients were suffering from a moderate to severe disease, according to DAS28-ESR (mean at baseline 4.8±1.2, range 1.82-7.72). Seventy-six patients resistant to conventional DMARDs therapy started therapy with either adalimumab (n=27) or etanercept (n=49), homogeneously distributed within the 4 categories 
Laboratory parameters
Complement. Laboratory features at baseline of the whole RA cohort compared with controls are shown in Table II . The RA cohort showed mean baseline C3 and C4 levels significantly higher than controls (p values 0.0012 and 0.0003 by paired t-test, respectively), and similar CH50. In the RA cohort, no significant differences in complement C3, C4, and CH50 were observed between ACPA-positive and ACPA-negative patients at baseline, regardless of the DMARD used (Fig. 1 ). In addition, when further stratifying for the presence or absence of RF no significant differences were observed (data not shown).
" Table III shows the laboratory features of the, 76 patients treated with anti-TNF at baseline, 14 arid 22' weeks. At baseline, no differences were observed between the anti-TNF treated and non-treated of RA patients (Table I) patients and also in this group mean baseline C3 and C4 levels were significantly higher than controls (p<O.OOI).
When comparing the changes in complement levels in the anti-TNF treated group, there was a statistically significant decrease in C3 (Pc<O.003) and C4 (Pc<O.005) levels at both 14 and 22 weeks while CH50 levels remained unchanged (Pc=O.78) (Table III) . Interestingly, when comparing the levels of C3, C4, and CH50 at 14 and 22 weeks in the anti-TNF treated group, these were not different in respect to controls.
ACPA levels did not significantly change during the 22 weeks of therapy (Table III) . At 22 weeks, a slightly higher reduction in ACPA levels, although not statistically significant, was observed in the 27 patients who started adalimumab (P=O.07), compared with those who started etanercept (P=O.32). Conversely, levels of RF showed a statistically significant decrease at 22 weeks of follow-up (Pc=O.04, Table II ), independent of the anti-TNF agent administered.
When stratifying for ACPA or RF, no significant differences were observed in mean complement C3, C4 or CH50 levels at baseline, and the decrease in C3 and C4 was similar between the groups (data not shown).
We therefore studied whether such a decrease in C3 and C4 complement levels after anti-TNF therapy could be due to complement activation or rather to normalization of previously high levels of these complement components. To better address this issue we evaluated the eventual release of SP of C3 and B that were never detected in the patients either at baseline, or at 14 and 22 weeks.
Complement, autoantibodies and disease activity. Disease activity significantly improved at both 14 and 22 weeks ofanti-TNF therapy showing an average of a moderate EULAR response (P<O.OOOI, Table II ). 17.9% of patients achieved a good response, 35.7% a moderate response, and 46.9% low or no response at 22 weeks.
The baseline mean DAS28 were significantly higher in the patients who did not achieve EULAR response at 22 weeks compared with the responders (DAS28 5.2±O.9 vs 4.5±1.4; p<O.OOI). No differences were observed in baseline ESR, CRP, nor complement C4 and CH50 levels in the patients who did not respond at 22 weeks compared with the responders. Moreover, no statistically significant difference in changes ofRF, ACPA, complement C4 or CH50 levels explored by one-way ANOVA were observed between patients who had a better response (defined as an EULAR good response) compared with those who had moderate or no response at both 14 and 22 weeks. Nevertheless, a tendency of a higher reduction in complement C3 levels was observed in patients with good EULAR response. Patients with baseline lower (although normal) C3 levels appeared to be also those who had a better EULAR response, as shown in Fig. 2 .
Semi-quantitative analysis
We performed a semi-quantitative analysis, transforming variables as summarized in Table IV using Z scores of each variable. CH50 at baseline was associated with RF levels (X 2=9.464, p<O.05), with a higher number of patients showing CH50 below the normal values also having elevated or very elevated RF levels. We failed to find any association between elevated/normal/decreased C3, C4 or CH50 levels and highly elevated/elevated/low or absent ACPA. Higher levels of complement component C3 at baseline were significantly associated with a worse EULAR response at both 14 and 22 weeks (X 2=1O.347,p=O.034). The patients who had a lower reduction in C3 levels from baseline were those who achieved the lowest EULAR scores (X 2=22.793, p<O.OO 1). In a multivariable regression analysis performed to explore any association between EULAR response and RF,ACPA, C3, C4, CH50, the complement C3 was the only one associated with EULAR response (p=O.002).
Correlation analysis
We tested whether changes in complement levels correlated with changes in ACPA or RF levels. When Pearson's test was performed, CH50 negatively correlated with RF both at 14 and 22 weeks (Pearson's coefficient=-O.358, p=O.007 and Pearson's coefficient=-O.377,p=O.006, respectively). Conversely, no correlation was observed between changes in ACPA levels and changes in complement C3, C4, and CH50 levels.
At 22 weeks of follow-up, reduction in complement C3 and C4 positively correlated with decrease in ESR levels (p=O.012 and p=O.OOl, respectively), and C4 with CRP as well (p=O.023). Variations in complement levels did not correlate with changes in disease activity measured by DAS28.
DISCUSSION
Complement and autoantibodies
Our results showed that in our cohort of RA patients complement activity (CH50) correlated with RF. In fact, at baseline, reduced CH50 levels were associated with higher RF levels. After 22 weeks of anti-TNF therapy, CH50 levels increased and negatively correlated with RF levels. In addition, the number ofpatients with positive RF was significantly reduced at 22 weeks of anti-TNF.
On the contrary, complement activity was not related with ACPA levels. Indeed, C3, C4 and CH50 levels were not associated with the presence (or absence) of ACPA. Furthermore, after therapy with TNF antagonists, changes in C3, C4 or CH50 levels did not correlate with variations in ACPA levels that remained stable during the 22 weeks of follow-up.
Autoantibodies have the potential to activate the complement in vitro, and this was demonstrated for RF and recently for ACPA (6, 13) . However, the behaviour of the complement system in respect to these autoantibodies in vivo has not been fully addressed.
Inappropriate complement activation can lead to tissue damage and manifestation of disease. Complement factors and receptors have been called to play an important role in RA since the first report from Brodeur in 1991 (14) , and it is evident that synthesis and activation of complement take place at distinct sites within rheumatoid synovium (15) . Reduced levels of native complement components and increased levels of complement metabolites in the synovial fluid and synovial tissue of RA patients have implicated complement in the pathogenesis of RA (16) . It has been suggested that key components in complement activation, such as C3 and B, are produced locally in RA synovium rather than being plasma derived (17) . Aggarwal et al. recently demonstrated alternative pathway activation with formation ofthe membrane attack complex in patients with juvenile rheumatoid arthritis (18) . This provides a more conclusive evidence for the pathogenic significance ofcomplement activation in RA. Trouw et aI, from in vitro observations, suggested that complement activation could be involved in RA pathogenesis in ACPApositive patients (6) . This was not confirmed by our in vivo results that provided evidence that RF, rather than ACPA, plays a role in complement modulation. Of interest, in the joint space, the activation of complement cascade appears to be mediated principally by immune complexes (CIC) present in situ. These CIC seem to be RF-IgG complexes while currently no reports found APCA as local complement activators. Thus, following our results, it is not surprising that elevated RF levels are associated with complement consumption (at least of the C5b-C9 sequence) measured by CH50.
Complement, disease activity and anti-TNF treatment
Of note, another result from the present study was the association between complement C3 levels and response to anti-TNF therapy. Monitoring of disease activity by measuring complement or complement-derived markers has proved useful in other autoimmune diseases, such as SLE. Complement plays a fundamental role in the clearance of immune-complexes, a mechanism that, when deficient, can lead into the development of autoimmune conditions (19) .
It was found that the normalization of C3 complement levels came with a significant improvement of disease activity in RA patients treated with anti-TNF. Higher levels of complement C3 at baseline were significantly associated with worse EULAR response. The patients who had a lower reduction in C3 levels from baseline during the follow-up were also those who achieved the lowest EULAR scores. According to this, in a multivariable analysis, C3 was the only variable associated with EULAR response. We suggest that persistently elevated C3 levels could be considered a negative predictive factor influencing the outcome of anti-TNF therapy in RA.
Several studies have explored the potential predictors of response to anti-TNF therapy in RA, and most studies agreed that patients with high baseline DAS28 were less likely to achieve remission in all models at any time points of assessment, and that the higher the baseline DAS28, the lesser chance to achieve remission (20) . Acutephase reactants may also have a predictive value for treatment response. One study on patients with ankylosing spondylitis treated with anti-TNF showed that higher baseline levels of ESR and CRP may be associated with a better response rate, while Burmester et al demonstrated the opposite (21) (22) . We confirmed that higher baseline DAS28, as well as high acute phase reactants in terms of C3 and CRP, might be associated with a poorer response to anti-TNF. Following our results, complement baseline levels may have a predictive value for response to anti-TNF treatment.
The question whether anti-TNF agents may be responsible or not of complement activation in vivo remains to be debated. In our cohort, we observed relatively high levels of C3 and C4 at baseline, evidence of frequent observation in plasma of RA patients. It has been previously reported that in RA, as well as in other inflammatory conditions, the presence of abnormally, pathologically elevated complement C3 levels may reflect the presence of an underlining inflammatory process (23) . We can suggest that the relatively high amount of plasma C3 could be due to spill over from the joints probably reflecting an in situ over-expression or even to an abnormal production of complement proteins due to inflammation (24) (25) . This could explain the reduction in complement C3 and C4 levels in the absence of complement activating cleavage fragments observed by us after treatment with TNF antagonists. In this view, C3 and C4 may act as acute phase reactants. For such reason we should consider reduction of complement native components as an improvement of a pre-existing pro-inflammatory status. Anti-TNF drugs have an outstanding anti-inflammatory potential that may be responsible for part of their mechanism in disease control. Nonetheless, Kaymakcalan and colleagues showed that adalimumab and etanercept do not induce complement-dependent cytotoxicity in activated normal human PBMC. Thus, it was supposed that complement lysis does not explain differences in the clinical efficacy profiles of these drugs (26) . According to this evidence, we studied patients treated with either ofthe two drugs, showing no differences in reduction of complement C3 and C4 levels.
To conclude, specific modulation and inhibition of local complement production could be an attractive target for RA therapy (27) , and another tessera has been added to the mosaic of mechanisms of damage mediated by pathogenic autoantibodies. Complement C3 could be of prognostic value in the assessment of response to anti-TNF therapy.
We believe that these data on in vivo observations may contribute to the unveiling of the mechanisms exerted by complement on RA pathogenesis.
